270 related articles for article (PubMed ID: 28185016)
41. PON1 polymorphisms are predictors of ability to attain HDL-C goals in statin-treated patients.
de Souza JA; Menin A; Lima LO; Smiderle L; Hutz MH; Van Der Sand CR; Van Der Sand LC; Ferreira ME; Pires RC; Almeida S; Fiegenbaum M
Clin Biochem; 2015 Nov; 48(16-17):1039-44. PubMed ID: 26079344
[TBL] [Abstract][Full Text] [Related]
42. Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity.
Sanghera DK; Manzi S; Minster RL; Shaw P; Kao A; Bontempo F; Kamboh MI
Ann Hum Genet; 2008 Jan; 72(Pt 1):72-81. PubMed ID: 17900266
[TBL] [Abstract][Full Text] [Related]
43. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus.
Flekac M; Skrha J; Žídková K; Lacinová Z; Hilgertová J
Physiol Res; 2008; 57(5):717-726. PubMed ID: 17949258
[TBL] [Abstract][Full Text] [Related]
44. The effect of
Çınar E; Akgöllü E; Yücebilgiç G; Bilgin R; Paydaş S
Nucleosides Nucleotides Nucleic Acids; 2022; 41(5-6):489-502. PubMed ID: 35306973
[TBL] [Abstract][Full Text] [Related]
45. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus.
Jiménez S; Tàssies D; Espinosa G; García-Criado A; Plaza J; Monteagudo J; Cervera R; Reverter JC
Ann Rheum Dis; 2008 Jun; 67(6):835-40. PubMed ID: 17728329
[TBL] [Abstract][Full Text] [Related]
46. Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population.
Gupta N; Binukumar BK; Singh S; Sunkaria A; Kandimalla R; Bhansali A; Gill KD
Gene; 2011 Nov; 487(1):88-95. PubMed ID: 21803130
[TBL] [Abstract][Full Text] [Related]
47. Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus.
Font J; Ramos-Casals M; Brito-Zerón P; Nardi N; Ibañez A; Suarez B; Jiménez S; Tàssies D; García-Criado A; Ros E; Sentís J; Reverter JC; Lozano F
Rheumatology (Oxford); 2007 Jan; 46(1):76-80. PubMed ID: 16801331
[TBL] [Abstract][Full Text] [Related]
48. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians.
Agrawal S; Tripathi G; Prajnya R; Sinha N; Gilmour A; Bush L; Mastana S
Indian J Med Sci; 2009 Aug; 63(8):335-44. PubMed ID: 19770524
[TBL] [Abstract][Full Text] [Related]
49. Association between Paraoxonase 1 (PON1) Polymorphisms and the Risk of Acute Coronary Syndrome in a North African Population.
Bounafaa A; Berrougui H; Ghalim N; Nasser B; Bagri A; Moujahid A; Ikhlef S; Camponova P; Yamoul N; Simo OK; Essamadi A; Khalil A
PLoS One; 2015; 10(8):e0133719. PubMed ID: 26241956
[TBL] [Abstract][Full Text] [Related]
50. Association analysis of PON2 genetic variants with serum paraoxonase activity and systemic lupus erythematosus.
Dasgupta S; Demirci FY; Dressen AS; Kao AH; Rhew EY; Ramsey-Goldman R; Manzi S; Kammerer CM; Kamboh MI
BMC Med Genet; 2011 Jan; 12():7. PubMed ID: 21223581
[TBL] [Abstract][Full Text] [Related]
51. Serum Paraoxonase activity in relation to lipid profile in Age-related Macular Degeneration patients.
AnandBabu K; Bharathidevi SR; Sripriya S; Sen P; Prakash VJ; Bindu A; Viswanathan N; Angayarkanni N
Exp Eye Res; 2016 Nov; 152():100-112. PubMed ID: 27693409
[TBL] [Abstract][Full Text] [Related]
52. Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Liamis GL; Kakaidi B; Tselepis AD; Cariolou MA; Elisaf MS
Arch Med Res; 2007 May; 38(4):403-10. PubMed ID: 17416287
[TBL] [Abstract][Full Text] [Related]
53. The most effective polymorphisms of paraoxonase-1 gene on enzyme activity and concentration of paraoxonase-1 protein in type 2 diabetes mellitus patients and non-diabetic individuals: A systematic review and meta-analysis.
Hashemi MM; Mousavi E; Arab-Bafrani Z; Nezhadebrahimi A; Marjani A
Diabetes Res Clin Pract; 2019 Jun; 152():135-145. PubMed ID: 31102685
[TBL] [Abstract][Full Text] [Related]
54. Genotype Ser413/Ser of PAI-2 polymorphism Ser413/Cys is associated with anti-phospholipid syndrome and systemic lupus erythematosus in a familial case: comparison with healthy controls.
Vázquez-Del Mercado M; García-Cobian TA; Muñoz Valle JF; Torres-Carrillo N; Martín-Márquez BT; Arana-Argaez VE; Best-Aguilera CR; Martínez-García EA; Petri MH; Núñez-Atahualpa L; Delgado-Rizo V
Scand J Rheumatol; 2007; 36(3):206-10. PubMed ID: 17657675
[TBL] [Abstract][Full Text] [Related]
55.
Grdić Rajković M; Popović-Grle S; Vukić Dugac A; Rogić D; Rako I; Radić Antolić M; Beriša M; Rumora L
J Clin Pathol; 2018 Nov; 71(11):963-970. PubMed ID: 29858231
[TBL] [Abstract][Full Text] [Related]
56. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population.
Arca M; Ombres D; Montali A; Campagna F; Mangieri E; Tanzilli G; Campa PP; Ricci G; Verna R; Pannitteri G
Eur J Clin Invest; 2002 Jan; 32(1):9-15. PubMed ID: 11851721
[TBL] [Abstract][Full Text] [Related]
57. Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome.
Kordi-Tamandani DM; Hashemi M; Sharifi N; Kaykhaei MA; Torkamanzehi A
Mol Biol Rep; 2012 Feb; 39(2):937-43. PubMed ID: 21573798
[TBL] [Abstract][Full Text] [Related]
58. Genetic variation at Q192R and L55M polymorphisms in PON1.
Mitra S; Kshatriya GK
Environ Toxicol Pharmacol; 2016 Jul; 45():251-6. PubMed ID: 27341351
[TBL] [Abstract][Full Text] [Related]
59. The role of PON1 and CYP2D6 genes in susceptibility to organophosphorus chronic intoxication in Egyptian patients.
Tawfik Khattab AM; Zayed AA; Ahmed AI; AbdelAal AG; Mekdad AA
Neurotoxicology; 2016 Mar; 53():102-107. PubMed ID: 26723569
[TBL] [Abstract][Full Text] [Related]
60. Osteopontin and interleukin-17A genes polymorphisms in Egyptian systemic lupus erythematosus patients: A relation to disease activity and severity.
Pasha HF; Tantawy EA; Youssef MA
Gene; 2019 Jun; 702():107-113. PubMed ID: 30898714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
